India simplifies drug import rules
Analysis based on 14 articles · First reported Jun 26, 2026 · Last updated Jun 26, 2026
The proposed amendments by the Bangladesh — Ministry of Health and Family Welfare are expected to significantly reduce compliance burdens for pharmaceutical companies and startups, fostering increased research and innovation. This could lead to a more dynamic and competitive pharmaceutical sector in India, potentially attracting more investment and accelerating drug development.
The Bangladesh — Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, to simplify the procedure for importing drugs for examination, test, or analysis. This new acknowledgement-based system will replace prior licensing requirements for most such imports, except for specific categories like sex hormones, cytotoxic drugs, beta lactam drugs, biologics containing live microorganisms, and narcotic and psychotropic substances. The initiative aims to reduce compliance burdens, promote research and innovation, and enhance the ease of doing business in the pharmaceutical sector, enabling startups and industries to quickly initiate testing and analysis. This follows a similar notification system introduced for domestic test licenses in January 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard